3 completed, 2 terminated, 1 active not recruiting, 1 no longer available. 5 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
| Phase 2 | 4 | Terminated 2, Active not recruiting 1, Completed 1 |
Follow aviptadil: new trials by email Literature Review of aviptadil trials Research Report on aviptadil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19 ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID | Phase 3 | Withdrawn | APR Applied Pharma Research s.a. | 2021-12-15 | 2026-05-14 | |
| Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS Aviptadil 67μg, Placebo 0.9% NaCl solution - Covid19, Corona Virus Infection | Phase 2 | Terminated | Prof. Dr. Jörg Leuppi | 83 | 2021-05-18 | 2024-01-18 |
| Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial) Aviptadil, Aviptadil Placebo, Corticosteroid - Covid19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 471 | 2021-04-20 | 2025-10-09 |
| ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 Remdesivir, Remdesivir Placebo, Aviptadil - Covid19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 473 | 2021-04-20 | 2025-10-24 |
| Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID | Phase 2 / Phase 3 | Terminated | APR Applied Pharma Research s.a. | 144 | 2021-02-15 | 2023-02-03 |
| I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients Remdesivir, Imatinib Mesylate, Dexamethasone - COVID-19 | Phase 2 | Active not recruiting | QuantumLeap Healthcare Collaborative | 1500 | 2020-07-31 | 2026-03-16 |
| Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure Aviptadil by intravenous infusion + standard of care, Normal Saline Infusion + standard of care - Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS) | Phase 2 / Phase 3 | Completed | APR Applied Pharma Research s.a. | 203 | 2020-05-15 | 2023-07-24 |
| ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE) ZYESAMI (aviptadil acetate) - Critical COVID-19 With Respiratory Failure | No longer available | APR Applied Pharma Research s.a. | 2023-02-03 |
COVID-19 (5) · Respiratory Distress Syndrome (5) · Coronavirus Infections (4) · Acute Lung Injury (3) · Coronaviridae Infections (2) · Dyspnea (2) · Nidovirales Infections (2) · RNA Virus Infections (2) · Respiratory Insufficiency (2) · Severe Acute Respiratory Syndrome (2) · Virus Diseases (2) · Disease (1)
APR Applied Pharma Research s.a. (4) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Prof. Dr. Jörg Leuppi (1) · QuantumLeap Healthcare Collaborative (1)
United States (6) · Switzerland (1)
Jonathan C Javitt, MD, MPH (4) · Prof. James Neaton (2) · Samuel Brown, MD (2) · Derek W Russell, MD (1) · Kathleen D Liu, MD (1) · Laura Esserman, MD (1)
PMID 34473343, PMID 34825704, PMID 36044317, PMID 36127739, PMID 36695483, PMID 36883141, PMID 37348524, PMID 39592213, PMID 40462830, PMID 42799508